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ABSTRACT 
Our immune system is a complex network made up of physical barriers and specialized 
proteins, cells and organs that all work together to prevent pathogens from causing disease in 
the body. Once the immune system has successfully mounted an immune response upon 
intrusion of a pathogen it will mount an immediate and stronger response against any 
subsequent exposure to it. This is known as immunological memory and is crucial for 
generating long-lasting protective immunity. The immune system has also developed to 
maintain homeostasis and be tolerant to the presence of the body’s own structures, or so 
called self-antigens. A loss of this tolerance can lead to the immune system attacking the 
body itself, causing autoimmune disease. The pathogenesis of autoimmune disease involves 
both genetic and environmental factors. B cells and autoantibodies are major contributors to 
several autoimmune diseases such as systemic lupus erythematosus (SLE). 
The aim of this thesis was to investigate the regulation of B cell responses in systemic 
autoimmune disease. This was studied in mouse models of autoimmunity and atherosclerosis 
and in paper III also in SLE patient samples. 
Paper I was prompted by a study where transfer of spleen B cells from old atherosclerosis-
prone apolipoprotein E-deficient (ApoE-/-) mice to young ApoE-/- mice conferred protection 
against plaque development. We characterized the B cell response in the spleen of 
atherosclerotic ApoE-/- mice and found an ongoing B cell response in the form of germinal 
center B cells and plasma cells. Repeated injections of apoptotic cells, carrying the same 
oxidation-specific epitopes as oxidized LDL, into young ApoE-/- mice led to the same 
activated phenotype, lowered cholesterol levels and protected against plaque development. In 
paper II the memory response to apoptotic cell-derived self-antigens was characterized. 
Upon primary immunization of apoptotic cells a transient autoantibody response against the 
self-antigens DNA and phosphorylcholine was induced and when the primary response had 
waned, a single boost injection of apoptotic cells led to a rapid induction of the same 
autoantibodies. In a second recall response to apoptotic cells, mice presented with signs of 
autoimmune pathology such as IgG-deposition in the kidneys, positive anti-nuclear staining 
of antibodies from sera and altered architecture of the glomeruli indicating kidney damage. In 
paper III a role for the scavenger receptor CD36 on B cells was investigated in the context of 
apoptotic cell-derived self-antigens. CD36 inhibited B cell activation in the response to 
apoptotic cells and associated with known negative regulators of autoimmunity; the tyrosine 
kinase Lyn and FcγRIIB. Upon break of tolerance to the administered apoptotic cells and the 
activation of autoreactive B cells, the level of CD36-expressing marginal zone B cells was 
dramatically decreased and the same population of cells was found to be decreased in the 
circulation of SLE patients compared to healthy individuals. 
In summary, the work presented in this thesis shows how B cell responses are regulated in 
different autoimmune contexts. A protective role for B cell responses in atherosclerosis was 
found, as well as a novel co-receptor involved in the response to self-antigens and the 
memory response to apoptotic-cell derived lupus-related self-antigens has been characterized 
in more detail than ever before. These findings are important for the understanding of B cell 
regulation in autoimmunity and can be implemented to inhibit harmful and promote 
protective responses in therapeutic approaches to combat autoimmune disease. 
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1 INTRODUCTION 
1.1 THE IMMUNE SYSTEM 
Our immune system protects us from pathogens in our environment, such as bacteria, viruses 
and fungi. It is a complex network made up of physical barriers and specialized proteins, cells 
and organs that all work together to prevent pathogens from causing disease in the body. 
Once the immune system has successfully mounted an immune response upon intrusion of a 
pathogen it will remember it and can more effectively and rapidly fight a reoccurring 
intrusion of the same pathogen. This is called immunological memory and is one of the 
hallmarks of our immune system. Another crucial task for the immune system is to maintain 
homeostasis as well as be tolerant to the presence of the body’s own structures and proteins, 
or so called self-antigens. A loss of this tolerance can lead to the immune system attacking 
cells and tissues of the body itself, causing autoimmune disease [1].  
The various cells, receptors and other mediators that make up the immune system are 
typically classified as belonging to either the rapid and broader innate immune system or the 
slower but more specific adaptive immune system. It should however be stated that the two 
systems very much depend on each other and that there are for example immune cells that 
belong to the adaptive immune system but show innate features in the way they recognize 
and respond to antigen [2, 3]. 
1.1.1 Innate immunity 
The separation between the innate part of the immune system and the adaptive is based a lot 
on antigen recognition. Immune cells of the innate immune system express receptors which 
are encoded in our germline DNA and therefore as opposed to in adaptive immune 
recognition do not require gene rearrangement. These germline encoded receptors recognize 
molecular patterns such as lipopolysaccharide (LPS), lipoteichoic acid and glycans and have 
been conserved through evolution to protect us from pathogens with these structures. These 
receptors are collectively termed pattern recognition receptors (PRR) because they recognize 
pathogen-associated molecular patterns (PAMP) [4]. PRRs can be membrane bound receptors 
but they can also be located in the cytosol and some are functional only when secreted. A 
family of essential PRRs are the Toll-like receptors (TLR) where some are membrane bound 
and some are intracellular and the various family members are categorized based on what 
class of PAMP they bind. The TLR that was first identified as a PRR was TLR4 for its ability 
to bind LPS; a major component of gram-negative bacteria. Intracellular TLR3, -7, -8 and -9 
are instead located in the endosomal compartment where they can sense PAMPs of microbial 
nucleic acids such as single-stranded RNA and unmethylated CpG dinucleotides. TLR2 can 
only function upon heterodimerization with either TLR1 or -6 which could lead to an 
increased ligand specificity [5]. TLR heterodimers can also associate with other receptors and 
in this way facilitate binding and uptake of antigens [6]. This phenomenon is considered in 
more detail in section 1.5.  
Another class of PRRs are the scavenger receptors (SR). They bind to a broad range of 
epitopes found on both microbes, modified lipids and apoptotic cells and as the name implies 
scavenge or clean the body of these antigens. As a group they are fairly diverse in structure 
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and are classified more based on their common function. In the context of innate immunity 
they play an important role in phagocytosis and cell adhesion [7]. For their ability to bind 
modified lipids and apoptotic cells they have also been implicated in the context of 
atherogenesis and autoimmunity respectively [8, 9]. A role for the class B scavenger receptor 
CD36 on B cells is the focus of paper III. 
Oxidation is constantly occurring in nature and in our bodies. As a result of oxidative 
processes, oxygen reactive species are formed and these can in turn oxidize lipids, proteins 
and DNA creating so called oxidation-specific epitopes. Epitopes like this are, although being 
self-epitopes, recognized as damaged structures that could cause danger to the host if not 
taken care of by the innate immune system [10]. Oxidation-specific epitopes are recognized 
and bound by PRRs and have therefore come to be referred to as danger-associated molecular 
patterns (DAMP) and some of the epitopes also share molecular mimicry with PAMPs. An 
immune response triggered by DAMPs gives rise to what has been termed sterile 
inflammation as it occurs in the absence of pathogen [11]. The first example of a disease 
caused by sterile inflammation is gout, where hyperuricemia nucleate crystals of 
monosodium urate deposit in joints inciting an acute inflammatory response [12]. One of the 
oxidation-specific epitopes most studied is phosphorylcholine (PC) which is present on both 
oxidized lipids, apoptotic cells and also some pathogens such as Streptococcus pneumoniae 
[13]. Understanding the regulation of immune responses elicited against oxidation-specific 
epitopes is central to this thesis and is considered in more detail in section 3 and in the papers. 
The cellular entity of the innate immune system is made up of monocytes, macrophages, 
dendritic cells (DC) and neutrophils belonging to the myeloid lineage of immune cells, as 
well as natural killer (NK) cells and innate lymphoid cells (ILC). Macrophages and 
neutrophils are phagocytic cells which after recognition of microbes by PRRs can 
phagocytose or engulf them and then destroy them in intracellular vesicles. Monocytes are 
abundant in the circulation and can upon inflammation migrate into tissues and further 
differentiate into macrophages. Dendritic cells are so called antigen-presenting cells (APC) as 
they present antigen to T cells and thereby form a very important bridge between innate and 
adaptive immunity. Although the DC is often appreciated for its antigen presenting capability 
it should be noted that also macrophages and B cells are APCs [1]. 
A consequence following binding of PRRs as well as an essential driver of inflammation in 
innate immunity is the activation of the inflammasome; a multiprotein complex present in 
myeloid cells. As described myeloid cells use PRRs to bind to and phagocytose pathogens, 
modified antigens and danger-associated ligands. Well in the cytosol the engulfed material 
can be further sensed by intracellular PRRs such as NOD-like receptors (NLR) and they can 
in turn bind the adaptor protein ASC (apoptosis-associated speck-like protein containing a 
caspase activation and recruitment domain). Now the inflammasome is formed and can go on 
to cleave pro-caspase 1 into its active form caspase 1 and this enzyme can cleave pro-
interleukin 1β (pro-IL1β) and pro–IL18 into the active cytokines IL-1 and IL-18 [14]. IL-1β 
is one of the most important cytokines to drive inflammation, both by recruiting other innate 
immune cells and activating vascular endothelium and lymphocytes [15]. Hence, activation 
of the inflammasome is crucial in regulating the inflammatory response elicited by the innate 
immune system. The inflammasome has also been shown to affect the subsequent adaptive 
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immune response as well as play a role in atherosclerosis, a mechanism that we could 
contribute more evidence to in paper I [16, 17].    
There are some immune cells that are more difficult to categorize as belonging to the innate 
or adaptive immune system. That is because they express antigen receptors that have gone 
through somatic gene rearrangement, a hallmark of adaptive immunity. At the same time 
these cells have the ability to, or even preferably, respond to antigen in the first line of 
defense. Antigen receptors of these cells, although rearranged to some degree, are more 
conserved. Similar to PRRs of the innate immune system, they have to a greater extent 
affinity for ligands with PAMPs or DAMPs as opposed to conventional lymphocytes of the 
adaptive immune system. These so called innate-like lymphocytes are γδ T cells, natural 
killer T (NKT) cells, B1 cells and marginal zone B cells (MZB) [18, 19]. B cell regulation is 
central to this thesis and MZBs and B1 cells will be further described in section 1.2. 
Innate immunity is the initiator of inflammation but when innate immune defenses are not 
sufficient to overcome the intrusion of a pathogen more specific effector cells are needed. 
Cues from the innate immune system are necessary for dictating an appropriate adaptive 
immune response to a particular pathogen. 
1.1.2 Adaptive immunity 
Adaptive immunity is as opposed to the inherent innate immune system and as the name 
implies something that develops during the lifespan of an individual as an adaptation to the 
intrusion of a specific pathogen. This is mirrored in the diversity and specificity of the antigen 
receptors of B cell and T cell lymphocytes; the major cellular components of adaptive 
immunity. This level of specificity however comes at a prize as adaptive immunity takes days 
to develop in contrast to the innate immune response which is initiated within minutes or 
hours. Activation of adaptive immunity is also very much dependent on the innate immune 
system and once activated, the adaptive immune system can in return potentiate innate 
effector mechanisms [1]. 
The B cell receptor (BCR) and T cell receptor (TCR) are membrane bound antigen-
recognition receptors. They are part of the immunoglobulin (Ig) superfamily of proteins and 
encoded in the Ig loci of B cells or tcr loci of T cells [20]. The way that these receptors are 
assembled is unique as the ready receptor is encoded by the joining of different gene 
segments in somatic tissues in a process known as V(D)J recombination [21, 22]. In this 
process one variable (V), one joining (J) and sometimes one diversity (D) gene segment are 
joined together. The incredible diversity amongst these receptors as a result comes from both 
combinatorial diversity because of the immense number of different combinations of the 
three gene segments that can be formed, and also junctional diversity as the segments are 
joined in a non-absolute manner [23]. To accomplish this intricate recombination of different 
gene segments two crucial lymphocyte-specific proteins are needed, namely the RAG-1 and 
RAG-2 enzymes. They are specifically co-expressed in only B and T cells and are 
responsible for the actual cleavage of the gene segments [24]. 
As mentioned in section 1.1.1 the presentation of antigen by DCs to T cells is an important 
step in an immune response to activate the adaptive immune system. As opposed to the BCR 
which can bind free antigen the TCR can only bind to antigen peptides presented by a major 
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histocompatibility complex (MHC) molecule on the surface of an APC. MHC class I 
molecules present antigens processed in the cytosol and are recognized by CD8 T cells, while 
MHC class II molecules present antigens processed in endosomal compartments and are 
recognized by CD4 T cells. These molecules were first discovered for causing rejection of 
transplanted tissues because they were recognized as foreign by the recipient’s immune 
system [25]. The binding of the TCR to the antigen-MHC complex is the first activating 
signal. The second signal is provided by co-stimulatory molecules and depending on the 
pathogen the third signal is provided by different sets of cytokines produced by the APC. 
These three signals will activate the T cell to undergo clonal expansion and differentiation 
into a number of effector T cell subsets. Which subset is governed by the nature of the 
antigen [26]. 
A B cell also gets its first activating signal from binding the antigen with its BCR. The 
endocytosed antigen is then displayed on the surface of the B cell in an MHC class II 
molecule. Unlike T cells, B cells are also APCs. The second signal is given by an antigen-
experienced T cell that recognizes the antigen-MHC complex. T cells that provide this B cell 
help are called T follicular helper (TFH) cells. They are CD4 T cells and specifically express 
the B cell follicle homing receptor CXCR5 [27]. A properly activated B cell can differentiate 
to become a germinal center (GC) B cell, a memory B cell or an antibody-producing plasma 
cell. B cells can also become activated without T cell help. Different pathways of B cell 
activation and B cell fates will be described in detail in section 1.2.3.  
1.1.2.1 Humoral immunity 
One of the most important effector functions of B cells in an immune response is to produce 
antibodies that can in turn neutralize pathogens, help phagocytes to recognize pathogen for 
engulfment and activate the complement system. An antibody is the soluble form of a BCR 
and consists of a constant region that determines its effector function and a variable region 
that determines the antigen-binding specificity. It has a two-fold axis of symmetry and has 
two identical heavy chains containing both the constant and variable region and two identical 
light chains containing only the variable region. The constant region of an antibody, also 
called Fc region, consists in five classes or isotypes; IgM, IgD, IgG, IgE and IgA. The BCR 
of a non-activated or naïve B cell is always of the IgM isotype but following activation the 
isotype can be switched to another isotype class with effector functions needed to better fight 
the pathogen in question. The regulation of isotype class switching is partly mediated by 
cytokines secreted from activated T cells and can be considered the third signal in B cell 
activation [1]. 
IgG antibodies can trigger effector responses such as macrophage phagocytosis, ADCC 
(antibody-dependent cell-mediated cytotoxicity) by NK cells, neutrophil activation and 
inhibition of B cell activation by immune complexes (IC) by binding to Fc receptors (FcR). 
As the name implies the antibody binds the receptor with its Fc region. Studies where FcRs 
were first identified showed that the binding was independent of the variable part of the 
antibody, the so called F(ab) region [28]. There are activating FcRs that signal through an 
immunoreceptor tyrosine-based activation motif (ITAM) and there is one inhibitory FcR; 
FcγRIIb, that signals through an immunoreceptor tyrosine-based inhibitory motif (ITIM) 
[29]. Since FcRs are expressed on a variety of immune cells and can be both activating and 
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inhibitory they have the ability to regulate an immune response both in the innate and 
adaptive branch and play an important role in both clearing an infection but also in governing 
anti-inflammatory responses and tolerance [30]. 
1.1.2.2 Immunological memory 
A hallmark of adaptive immunity is the creation of long-lasting protective immunity 
following the first encounter of a pathogen by the immune system. This phenomenon is 
called immunological memory as the immune system remembers the pathogen upon a second 
encounter and therefore can mount a faster and more efficient immune response compared to 
the primary encounter. This concept is the biological foundation in vaccine development 
where extensive research is being done on how to enhance and regulate both the cellular and 
humoral components of a memory response to develop potent vaccines [31, 32]. 
The major components of immunological memory are memory B and T cells and long-lived 
plasma cells which reside in the bone marrow where they constantly produce antibodies. 
They are actually contributing to a large fraction of the total amount of antibodies in the 
circulation and they can reside in the bone marrow for a lifetime [33]. Whether the long-lived 
plasma cell pool in the bone marrow is being continually replenished by memory B cells in 
the periphery or if its survival in the bone marrow is dependent upon a local survival niche is 
still being debated and there are some competing concepts [34]. In every recall response to a 
certain antigen the antibodies produced will be of higher affinity for the antigen as they have 
gone through more rounds of selection and this also adds to the increased efficiency of a 
memory response. Hence, the more times a pathogen is recalled the more efficient the 
immune system will be in combating it [35]. In paper II we investigate how some of these 
processes are similar but interestingly also differ in the memory response to a self-antigen. 
1.1.3 The spleen 
All immune cells develop from hematopoietic stem cells in the bone marrow, except for a  
specialized B cell subset that is derived from the fetal liver and neonatal bone marrow and so 
called tissue resident macrophages which are derived from the embryonic yolk sac [36, 37]. 
The thymus and the bone marrow are both classified as central or primary lymphoid organs 
because they are home to developing immature progenitors of immune cells. Although the 
thymus is the most important organ for T cell development, T cell progenitors also stem from 
the bone marrow. When cells leave the bone marrow they go to secondary lymphoid organs 
to continue their  development or differentiation upon activation. Secondary lymphoid organs 
are lymph nodes, the GALT (gut-associated lymphoid tissue) and the spleen. Due to the types 
of responses investigated in this thesis this chapter will focus on the anatomy and function of 
the spleen in the immune system. 
The spleen is divided into areas of red pulp and white pulp. The red pulp is so called because 
here is where blood is filtered through the spleen in a specialized structure of veins. Red pulp 
macrophages also make up this area and thereby have an ideal positioning for phagocytosing 
senescent erythrocytes, an important function of the spleen. The white pulp is the lymphoid 
compartment where the positioning of B cell follicles and T cell zones or periarteriolar 
lymphoid sheaths (PALS) makes for an excellent setup of B and T cell cross-talk and is quite 
similar to the structure in other secondary lymphoid organs [38]. 
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The spleen also harbors a unique anatomical 
structure called the marginal zone which borders 
the red and white pulp. Here, specialized subsets 
of macrophages and B cells reside in an 
opportune location to capture and respond to 
blood-borne antigens, as the marginal zone is 
where blood is being filtered into the spleen 
through a sinusoid system to eventually enter the 
red pulp. Marginal zone macrophages (MZM) 
and marginal metallophilic macrophages are 
macrophage subsets specific to the marginal zone 
(Figure 1). In addition to their opportune 
location, they also express sets of PRRs that are 
well suited to bind the blood-borne antigens 
entering the marginal zone. The MZMs can 
provide the MZBs with antigen and MZBs are in 
turn specialized to respond to blood-borne 
antigens and can also transport antigen and ICs 
into the follicle and deposit it on follicular 
dendritic cells (FDC) [39, 40]. 
 
1.2 B CELLS 
B cells develop in the bone marrow but the B in B cell does not stand for bone marrow but 
for bursa of Fabricius, a lymphoid organ in chickens where B cells were first discovered back 
in 1965. This groundbreaking study by Cooper and colleagues established the B cells and T 
cells as separate lineages originating from either the bursa (B) or thymus (T). From their 
studies of irradiated chickens they could also attribute hallmark immune effector functions to 
either subset. The B cells were responsible for antibody responses and the T cells for cellular 
effector functions such as delayed-type hypersensitivity and graft-versus-host rejection [41]. 
The discovery has shaped the course of modern immunology and greatly contributed to the 
study of immunodeficiency conditions, cancer and autoimmunity. The B cell is classically 
considered as a cell belonging to the adaptive part of the immune system that requires T cell 
help to become activated and subsequently differentiate and produce antibodies to attenuate 
infection. But B cell biology is diverse and there are different B cell subsets that are located 
in different anatomical locations in the body and they differ in their antigen recognition 
properties and activation pathways. In this chapter the development and diversity of B cells 
and their activation during the course of an immune response will be described. 
1.2.1 B cell development 
The bone marrow is the primary location for early B cell development from stem cell to 
immature B cell and development from immature to mature B cell takes place in secondary 
lymphoid organs. Alternative locations for early B cell development are also the fetal liver 
and the lamina propria of the gut [37, 42]. Development in the bone marrow starts with the 
Figure 1. Histology of a mouse spleen showing the 
follicles surrounded by the marginal zone and the 
red pulp. Stained for MARCO – MZMs (red), 
MOMA1 – marginal metallophilic macrophages 
(green) and F4/80 – red pulp macrophages (blue). 
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early pro-B cell and consists of a number of steps during which V(D)J recombination takes 
place to assemble a functional BCR. In each step a gene rearrangement takes place to produce 
another protein chain of the BCR and successful rearrangement is basically the cue for 
moving on to the next stage. This process is tightly regulated to ensure the high specificity 
and thereby diversity of the resultant B cell repertoire, that each B cell only expresses BCRs 
with a singular specificity and also to avoid the production of B cells with high specificity to 
self-antigens, as this could cause autoreactive immune responses and as a result autoimmune 
disease. During V(D)J recombination, there is no control for the fact that the BCR generated 
from gene rearrangements will not be reactive towards self-antigens. There are however 
checkpoints both in the bone marrow and the periphery to ensure that B cells are tolerant to 
self-antigens [43]. 
As much as 75 % of early immature B cells have been estimated to display auto-reactivity. 
There are however control mechanisms at play to minimize the amount of self-reactive 
immature B cells exiting the bone marrow. The BCRs of immature B cells are tested for self-
reactivity by the surrounding tissue in the bone marrow. If a B cell reacts to one of these 
antigens it can try to rearrange its light chains once again, a process known as receptor 
editing. A B cell can go through several rounds of receptor editing but if it has used up all its 
V-J segments and is still autoreactive, apoptosis is induced, a concept known as clonal 
deletion. A third mechanism is often induced when the self-antigen is only weakly cross-
linking, as is the case for some small soluble proteins. This induces a state of 
unresponsiveness or anergy, which means the cell is viable and can still exit to the periphery 
but well there cannot be activated upon antigen encounter [44]. Together these mechanisms 
create so called central tolerance but in spite of this about 40 % of B cells leaving the bone 
marrow are still self-reactive. This makes sense though as not all antigens of the body can be 
presented in the bone marrow. Thankfully there are similar mechanisms in the periphery to 
induce tolerance. Also here, B cells can undergo clonal deletion or receptor editing upon 
encounter of a self-antigen or be induced to a state of anergy and these mechanisms are 
responsible for peripheral tolerance [45, 46]. About 20 % of peripheral mature B cells are 
however still autoreactive, although largely against cytoplasmic antigens which could be 
explained by the fact that they are less accessible for antigen-recognition during B cell 
development [43]. 
After V(D)J rearrangement and assembly of a functional BCR that has been tested for self-
reactivity, B cells leave the bone marrow as transitional B cells, so called as they are 
transitioning from immature to mature B cells. When B cells get ready to leave the bone 
marrow they acquire an increased density of IgM on their surface and upon exit they also 
acquire the surface expression of IgD [47]. The transitional B cells home to the spleen where 
they can continue their development into fully mature B cells. There is some controversy 
regarding the developmental stages of transitional B cells into mature B cells, however they 
can be distinguished using different surface markers [48, 49]. The phenotype of these cells 
and other B cells will be described in the next section. 
1.2.2 B cell subsets 
There are transitional type 1 (T1) and transitional type 2 (T2) B cells. These are immature B 
cells that upon their exit from the bone marrow express IgM (the BCR) but as T1 B cells 
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differentiate into T2 B cells they acquire increased surface expression of IgD as well as other 
markers such as CD23 and CD21 [49]. Evidence has also been put forth supporting the 
existence of a third transitional B cell population, namely transitional type 3 (T3) B cells, 
which can be distinguished using an additional marker; AA4 [50]. Transitional B cells home 
to the spleen where they differentiate to mature B cells. 
The mature B cells are divided into B2 and B1 cells. The B2 cells are further divided into 
either follicular B cells (FOB) or MZBs. FOBs are the most abundant type of B cells and are 
as the name implies mainly located in B cell follicles in secondary lymphoid organs, but they 
also recirculate. Their positioning in B cell follicles opposite to the T cell zone make them 
well suited to respond to protein antigens in a conventional T cell-dependent (TD) immune 
response. MZBs are non-recirculating and only reside in the unique niche that is the marginal 
zone of the spleen. Phenotypically, MZBs are characterized by expressing high levels of 
CD21, CD1d and the SR CD36 [51]. CD21 on MZBs can help them to trap ICs in the 
marginal zone and transfer these into the follicle to deposit them on FDCs [52]. The 
expression of CD1d is important in presenting lipid antigens to iNKT (invariant NKT) cells 
[53]. A special functional characteristic of MZBs is how they respond rapidly to blood-borne 
antigens and how they are able to do this without T cell help [54]. A much debated question 
when it comes to FOBs and MZBs is what determines whether a transitional immature B cell 
will develop into one or the other. So far some of the factors implicated in this fate decision 
are signaling through the BCR, Notch2, the B cell-activating factor of the tumor necrosis 
factor (TNF) family (BAFF) receptor and the nuclear factor-kappa-light-chain-enhancer of 
activated B cells (NF-κB) pathway [55, 56]. 
B1 cells are quite different from B2 cells. They are derived from the bone marrow but also 
from the fetal liver. B1 cell development in relation to B2 development is still not fully 
understood and there are two different hypotheses where one claims that they stem from 
distinct precursors and the other that they are derived from a common precursor [57]. B1 cells 
are located in the spleen but also constitute a large portion of immune cells in peritoneal and 
pleural cavities in the body. They are self-renewing and can be further divided into B1a and 
B1b cells. Their common phenotype when it comes to surface markers is 
CD19hiB220loCD43+CD23-IgMhiIgDlo. The B1a subset is however distinguished from the 
B1b cells on the basis of also expressing CD5 [37]. Another major characteristic of B1 cells 
is their ability to produce natural antibodies which are antibodies that are produced without 
the presence of pathogens as they have been shown to be present in germ-free mice at steady-
state [58]. It should however be noted that B1 cells are not the only source of natural 
antibodies, as MZBs are also capable of producing antibodies under homeostatic conditions 
[19]. 
There are also subsets of B cells with regulatory functions. It has been hard to reach a 
consensus on the phenotype of these cells and to date it is unknown how they are 
developmentally linked to each other and other B cell subsets. What is agreed upon though is 
the ability of these cells to produce the anti-inflammatory cytokine IL-10 [59]. Subsets that so 
far have been reported to do so are T2-MZP (transitional type 2 marginal zone precursor) 
cells, MZBs, plasmablasts and a CD1dhiCD5+ B cell subset which has also been shown to 
differentiate into antibody-secreting cells after IL-10 production [60-64]. In addition to the 
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type of subset, the mode of activation is also of importance for inducing IL-10 and ligands 
engaging the BCR and TLRs have been shown to elicit IL-10 production from B cells [65]. 
The majority of the work in this thesis is based on studies in mice and therefore the B cell 
subsets described so far are murine B cell subsets. However, I would like to in a simplified 
manner mention the main phenotypes of the human peripheral circulating B cell subsets 
investigated in paper III, with regard to surface markers. Human peripheral circulating B cell 
subsets can be divided into transitional immature, naïve mature and memory B cells. In 
humans, plasmablasts and MZBs can actually also be found in the circulation [66, 67]. Naïve 
B cells, memory B cells and MZBs can be divided by their differential expression of CD27 
and IgD. CD27 is a marker for memory B cells but is not present on immature or mature B 
cells, except for MZBs. IgD can then be used to distinguish between memory B cells and 
MZBs, where memory B cells are IgD-. There are a lot more specific surface markers for 
these subsets and the markers mentioned do for instance not distinguish between transitional 
immature and mature B cells [68].    
Once activated, a B cell will differentiate into different activated B cell subsets which are the 
GC B cells, plasmablasts and plasma cells and memory B cells. Depending on the subset and 
antigen in question there are a number of different activation pathways for B cells to take, of 
which will be discussed in more detail in the following section. 
1.2.3 B cell activation 
The activation of B cells can occur with or without T cell help or in so called T cell-
dependent (TD) responses and T cell-independent (TI) responses. The type of response 
depends a lot on the antigen in question and antigens can therefore also be classified as being 
TD or TI. 
TI responses can be further divided into TI type 1 (TI-I) and TI type II (TI-II) responses. TI-I 
B cell activation is independent of engagement of the BCR and can be accomplished through 
TLR activation alone. A classic example is the binding of LPS to TLR4, something that has 
also been taken advantage of extensively in experimental research to activate B cells both in 
vitro and in vivo. TI-II responses on the other hand are dependent on engagement of the BCR, 
or rather cross-linking of numerous BCRs. This is accomplished by the fact that TI-II 
antigens often are long polysaccharides with many more or less identical antigenic sites. In a 
TD response the second signal is given by the T helper cell, but in TI responses help in form 
of a second signal for activation can come from other cells such as DCs, neutrophils and 
NKT cells [69]. And although T cell help is not essential in TI responses, T cells have been 
shown to play some role in regulating the response [70]. The innate-like B cell subsets MZBs 
and B1 cells are more prone to respond to TI antigens. Their BCR repertoire is rich in germ-
line encoded specificities found on TI antigens, such as microbial carbohydrates, glycolipids 
as well as on self-antigens such as apoptotic cells [71]. Upon activation of their antigen, 
whether it’s a TI-I or TI-II antigen, these cells will rapidly differentiate into short-lived 
extrafollicular plasma cells [72]. The differentiation of MZBs and B1 cells into antibody 
producing plasma cells is the most abundant differentiation pathway for these types of 
responses. However, there is also some evidence to support that these cells can form abortive 
GCs and that TI-II immune responses generate memory B cells [73, 74].  
 10 
TD antigens are protein antigens and although MZBs and B1 cells can participate in TD 
responses, they most commonly involve the activation of FOBs. The three signals required to 
activate a B cell in response to a TD antigen were briefly described in section 1.1.2. Once 
properly activated, the B cell can either enter the GC or directly differentiate to antibody 
producing plasma cells. 
1.2.3.1 The germinal center 
The GC is a specialized structure that appears in the follicles of secondary lymphoid organs 
during the course of a TD response. It consists of antigen-specific activated B cells that are 
undergoing clonal expansion and also manipulation of their BCRs to ultimately create B cells 
that are more efficient in clearing the pathogen in question [75]. When a B cell meets its 
antigen and is initially activated, it will upregulate CCR7 (chemokine receptor 7) and in 
response to CCL21 (chemokine ligand 21) migrate towards the T cell zone and in the T-B 
border is where GCs are formed. At this point the GC B cells upregulate an enzyme called 
activation-induced cytidine deaminase (AID), which together with other enzymes is 
responsible for somatic hypermutation (SHM) and class switch recombination (CSR) [76]. 
SHM is a process where random point mutations are introduced in the variable-region gene 
segments of the BCR and this results in B cells with altered affinity for the antigen. Since the 
mutations are random, both B cells with unchanged, higher or lower affinity for the antigen as 
well as self-reactive B cells can be generated. In order to select for and further expand only 
the B cells with sufficiently high affinity for the antigen, there is a specialized subset of cells 
in the GC called FDCs. Contrary to what the name implies, these cells are not DCs but were, 
when first discovered, mistaken to be because of their dendritic morphologic appearance. 
They are stromal in origin and unlike professional APCs they do not present antigen in an 
antigen-MHC complex but uses complement and FcRs for this purpose [77]. The presentation 
of antigen by FDCs to B cells in the GC reaction allows for antigen-driven selection and 
affinity maturation of the cells with the highest affinity for the antigen. The GC is divided 
into a dark zone, where proliferation and SHM takes place and following this B cells migrate 
to the light zone, where the FDCs are located and antigen-driven selection takes place. B cells 
that don’t get selected undergo apoptosis and are phagocytosed by specialized macrophages 
called tingible body macrophages [78]. Defects in these macrophages have been linked to 
autoimmune disease, presumably because of the resultant accumulation of apoptotic cells 
[79]. CSR is the other AID-induced process that takes place in a GC and as the name implies 
means a switch of the isotype class of the BCR which will always, for a previously antigen- 
inexperienced B cell, be IgM and IgD. Different antibody subclasses have different effector 
functions and the choice of isotype in this process depends on the cytokine milieu induced by 
the pathogen. It should however be mentioned, that CSR has also been shown to occur 
independently of AID and the GC [80].  
As described B cells need T cell help in a TD response to at all enter into a GC reaction, but 
also in the later stages of the reaction, there is a specific type of T cell that is extra helpful and 
essential for generating high-affinity antibody responses and B cell memory. These are TFH 
cells and they are a separate subset of T helper cells. They express CXCR5, programmed cell 
death protein 1 (PD-1), ICOS and CD40L and secrete the cytokine IL-21. The interaction of 
affinity maturation-selected B cells and TFH cells is the last checkpoint before the B cell 
leaves the GC and goes on to become a memory B cell or an antibody producing plasma cell. 
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However there is also a third option for the B cell, to re-enter the GC reaction and go through 
more rounds of SHM. The presence of TFH cells is important for the persistence of GCs. The 
lack of TFH cells aborts GCs, showing how essential of a checkpoint this specific T cell help is 
for further differentiation, but also for regulation of self-reactive GCs [79]. More specifically, 
a limiting role for TFH cells in GC B cell selection was also recently shown to be dependent 
on the amount of antigen presented on MHCII to the TFH cell which responds by secreting IL-
4 and IL-21 [81]. 
1.2.3.2 Plasma cells 
Upon activation, B cells can differentiate to antibody producing plasmablasts and plasma 
cells. Plasma cells have a slightly extended endoplasmic reticulum and a bigger cytoplasm 
than other B cells, as to maintain the production, storage and secretion of large quantities of 
antibodies [82]. They are characterized by their expression of CD138 and low expression of 
the pan B cell marker B220 and the expression of the transcription factor Blimp-1 [83]. 
In a TI response, activated B cells can move to medullary chords in lymph nodes and 
extrafollicular focis in the spleen to differentiate to plasmablasts and eventually plasma cells 
[84]. In a TD response the activated B cell can also take this route but can also enter the GC. 
GC B cells can further differentiate to long-lived plasma cells that home to the bone marrow 
where they can reside for a lifetime giving rise to antigen-specific antibodies [33]. Although 
this is where most of the long-lived plasma cells reside, a small population of long-lived 
plasma cells can also be found in the spleen [85]. Expression of CXCR4 by plasmablasts is 
important for the migration to extrafollicular sites and its ligand CXCL12 is indeed expressed 
in both extrafollicular focis, medullary chords and in the bone marrow [86]. The 
differentiation of activated B cells into plasmablasts at extrafollicular sites is associated with 
the loss of activation markers on the B cell’s surface such as MHCII, co-stimulatory 
molecules, CD19 and the BCR itself. An important factor in extrafollicular focis for the 
maintenance of plasmablasts and their subsequent differentiation into bonafide plasma cells 
has been shown to be a specific DC population located in these sites that expresses high 
levels of CD11c [87]. In summary, the early adaptive immune response involving the 
activation of both FOBs, B1 cells and MZBs, whether it be TI or TD, is crucial to mount  
antibody responses that can specifically and efficiently combat the infection against a large 
variety of pathogens. 
1.2.3.3 Memory B cells 
Another outcome of B cell activation, following both a TI and TD response and in both the 
follicular GC and extrafollicular pathway, is the generation of memory B cells. As the name 
implies, the existence of memory B cells upon re-encounter of a pathogen is essential for the 
efficient development of neutralizing antibody responses [35]. The classical view of the 
phenotype of a memory B cell is that its BCR is isotype switched and of high affinity for the 
antigen, as it has been generated through CSR and SHM processes in a GC reaction. 
However, new evidence has emerged showing that there are also GC-independent memory B 
cells [88, 89]. So what governs the fate decision of an activated B cell to enter the GC or not 
and ultimately become a memory B cell as a result of either pathway? A couple of different 
regulatory events have been suggested. Competition experiments using high- and low-affinity 
 12 
antigen specific B cells show that the early interaction with helper T cells could be of 
importance [90]. In more detail the SAP (signaling lymphocyte activation molecule-
associated protein) has been shown to be important for the duration of T-B cell contact at this 
stage and could therefore also be involved in the fate decision [91]. CD40 signaling and 
regulation of Bcl6 by the cytokine IL-21 have also been implicated in affecting the choice of 
pathway [88, 92]. Recently, a study showed that memory B cells and long-lived plasma cells 
are generated at different points in time during the course of a GC reaction and even that 
memory B cells with different effector functions are generated at different time points [93]. 
Affinity for the antigen is also important for the choice between differentiation into a memory 
B cell or a long-lived plasma cell, where high-affinity B cell clones have a propensity for 
differentiating into plasma cells rather than memory B cells [94]. In addition to memory B 
cells developed from varying degrees of T-B cell interactions, memory B cells can also be 
generated from TI responses. B1 cells have been shown to generate memory B cells in a TI 
manner, although the recall response in this case, as compared to TD memory, was more 
qualitative than quantitative [95]. In summary, the quality and features of a memory response 
will vary depending on involvement of a previous GC reaction, the level of T cell help if any, 
the type of B cell activated and the type of antigen. The B cell memory response to self-
antigens has been studied in much less detail and is something we provide more insight to 
with the findings in paper II. 
1.2.3.4 B cell signaling 
Events described so far concerning B cell activation have mainly been on a cellular level. 
However, like most cells, B cells have an intricate network of intracellular signaling proteins 
signaling in different pathways depending on what receptors that are engaged on the 
membrane surface. Pathways described in this section relates mainly to modes of B cell 
regulation investigated in paper III. 
The first activating signal of a B cell is the binding of antigen to the BCR. It has in numerous 
studies been shown how important this is for the cell fate decision of a B cell. It is critical 
both at the earliest stages of development in the bone marrow, in the transition from 
immature to mature B cell, in GC selection and SHM processes and in reactivation of 
memory B cells [96]. The binding of antigen to the BCR activates the protein tyrosine kinase 
Lyn of the Src family of kinases. The BCR is coupled to the signaling components Igα and 
Igβ that contain ITAMs in their cytoplasmic tails that can get phosphorylated by Lyn. This in 
turn leads to the phosphorylation of another tyrosine kinase Syk, that can in turn activate the 
phosphoinositide-3-kinase (PI3K) leading to the phosphorylation and conversion of the 
signaling protein phosphatidylinositol biphosphate (PIP2) to phosphatidylinositol triphosphate 
(PIP3). The generation of PIP3 recruits Bruton’s tyrosine kinase (Btk) and phospholipase C γ2 
(PLCγ2) to the membrane. This leads to a number of events such as the release of 
intracellular calcium and activation of downstream kinases and transcription factors NF-κB 
and nuclear factor of activated T cells (NFAT), which ultimately regulate the fate of the B 
cell [97]. The PI3K pathway and subsequent activation of the transcription factor FOXO1 has 
been shown to be the only pathway downstream of the BCR that is indispensable for B cell 
survival [98].  
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Figure 2. A simplified illustration of the two signaling pathways downstream  of FcγRIIB in the response to ICs. On the left: 
On B cells carrying a BCR, engagement of the BCR and FcγRIIB by ICs leads to the activation of SHIP which will inhibit 
proliferative BCR signaling. On the right: On plasma cells, lacking a BCR, cross-linking of FcγRIIBs leads to the SHIP-
independent activation of  Btk and JNK which induces apoptosis.   
 
Signaling events to inhibit B cell activation and as a result attenuate immune responses are of 
course also very important and are in principal mediated by in different ways interfering with 
the activating pathways described, downstream of the BCR. There are a number of inhibitory 
receptors on B cells such as CD22, PD-1 and paired immunoglobulin-like receptor B (PirB). 
However, the signaling downstream of FcγRIIB will be the focus of this chapter. FcγRIIB is 
the only FcR expressed on B cells [29]. FcγRIIB classically binds the Fc region of IgG ICs, 
which coligates the BCR with the antigen of the IC. Binding activates Lyn, which 
phosphorylates the ITIM of FcγRIIB. This in turn activates the SH2-domain-containing 
inositol polyphosphate 5' phosphatase (SHIP), which dephosphorylates PIP3, causing Btk and 
PLCγ2 to dissociate from the cell membrane, which inhibits calcium flux and proliferation 
(Figure 2 - left). SHIP has also been shown to inhibit other proliferative pathways, such as the 
ones governed by the survival factor Akt and the MAP kinase [99]. With regard to the Akt 
pathway, it should however be mentioned that it has a complex role in cell fate decisions and 
repression of it can yield both inhibitory and activating consequences as a result of the 
subsequent B cell response [100]. FcγRIIB is expressed also on GC B cells and plasma cells. 
GC B cells that have undergone SHM can have lower affinity for the antigen and plasma cells 
have completely downregulated their BCR. This presents a new scenario for the binding of 
ICs to FcγRIIb, which affects the signaling downstream of the receptor due to the lack of 
BCR engagement. This cross-linking of FcγRIIB induces an apoptotic pathway that is 
independent of SHIP, Lyn, the ITIM, Syk and PLCγ2 but instead engages Btk and the c-Jun 
N-terminal kinase (JNK) (Figure 2 - right) [101]. Another SHIP-independent pathway, 
following cross-linking of only FcγRIIb has been proposed, where the involvement of the Abl 
(Abelson murine leukemia viral oncogene homolog 1) family kinase results in cell cycle 
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arrest and apoptosis [102]. Both of these pathways have implications for the selection and 
affinity maturation of B cells in the GC, to avoid the selection of B cells with low affinity or 
possibly self-reactive BCRs. Also at the plasma cell stage these pathways are of regulatory 
value to attenuate the antibody production and immune response when the presence of ICs 
have reached potentially harmful levels. Indeed, it has also been shown that mice lacking the 
FcγRIIB, and hence these pathways of regulation, develop autoimmune features 
spontaneuosly and even autoimmune disease on certain genetic backgrounds [103]. 
 
1.3 AUTOIMMUNITY 
The first reference to the concept of autoimmunity was made by the German scientist and 
Nobel laureate Paul Erlich about a century ago when he coined the term horror autotoxicus. 
He described it as the immune systems’s tendency to only attack foreign entities and to avoid 
attacking self [104]. However failures in the immune system, whether they are due to genetic 
factors or dysregulation caused by environmental triggers, can result in immune responses 
against self-antigens and ultimately autoimmune disease. The components of the immune 
system with most relevance to the work of this thesis have been described and they will now 
be further considered in the context of autoimmunity. 
1.3.1 B cell regulation in autoimmunity 
As described in this thesis, B cells have several essential roles to play in an immune response, 
such as antigen presentation, cytokine production, memory and antibody production. For the 
same attributes, they have also been shown to be critical in promoting a variety of 
autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), 
diabetes and multiple sclerosis (MS) [105-108]. B cell targeted depletion therapy with 
rituximab is currently approved for treatment of RA and is undergoing evaluation in clinical 
trials for the use as treatment also for MS and SLE patients [109]. Here, I will touch upon 
some of the factors that can influence the regulation of autoreactive B cell activation. 
As described, there are both central and peripheral checkpoints to maintain self-tolerance. 
Weak cross-linking of the BCR by soluble proteins can lead to a state of anergy in the 
periphery. Immature anergic B cells cannot compete for entry into follicles and the marginal 
zone as normal B cells and usually have a half-life of only two to three days [110]. Factors 
that could influence the survival of these anergic self-reactive B cells are likely to play a role 
in autoimmunity. Transgenic mice that overexpress the survival factor BAFF suffer from 
autoimmunity with both circulating autoantibodies and glomerulonephritis caused by IC-
deposition in the kidneys and older mice have also shown hallmark symtoms of the 
autoimmune disease Sjögren’s syndrome [111, 112]. These mice also exhibit expanded pools 
of mature B cells and it is now known that the regulation of anergic self-reactive B cells in 
the periphery by BAFF is dependent on what stage of maturation the cell is in and that BAFF 
cannot rescue the cells that are more stringently deleted [113]. 
The dysregulation of various events in GCs and extrafollicular focis also contribute to 
autoreactive B cell responses. Some research carried out with the MRL.Faslpr autoimmune-
prone mouse strain crossed with mice transgenic for a BCR with affinity for the autoimmune 
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disease-related antigens DNA and rheumatoid factor (RF), actually show that the autoreactive 
response in this context bypasses the GC and takes place both in the T cell zone and in 
extrafollicular focis. There is also evidence supporting the fact that the plasmablasts in the 
extrafollicular focis have undergone isotype switch, somatic hypermutation and clonal 
expansion despite not having gone through the GC [114-116]. BAFF has as mentioned been 
implicated in autoimmunity and BAFF transgenic mice also display an expansion of 
plasmablasts at extrafollicular sites [111]. This highlights the importance of the extrafollicular 
pathway of activation in autoreactive B cell responses. 
TLR7 and TLR9 bind RNA and DNA ligands respectively, which are also common 
autoantigens and these receptors have been shown to contribute co-stimulation to autoreactive 
B cell responses. Synergistic engagement of the BCR and TLR9 by IgG2a-chromatin ICs can 
activate autoreactive B cells [117]. The same type of activation could later be established also 
for co-engagement of RNA-associated autoantigens of the BCR and TLR7 [118]. TLR co-
stimulation of B cells might even be more important than T cell help as they can induce both 
isotype switching and SHM in extrafollicular focis [119, 120]. The antigens mentioned are 
related to characteristic autoantibodies in SLE and these studies therefore provided new 
insight into why certain self-antigens might be preferred targets in this autoimmune disease.  
DCs are important regulators of autoreactive B cell responses in a number of ways. They can 
present antigen to autoreactive T cells, which can in turn influence the B cell response. They 
also possess the ability to present non-degraded antigen directly to B cells, which can 
enhance humoral responses and it is possible that this could also affect autoantibody 
responses [121]. They are also producers of BAFF and a proliferation-inducing ligand 
(APRIL) which can directly enhance plasmablast proliferation and autoantibody production 
by promoting survival of self-reactive anergic B cells [122]. 
Regulatory IL-10 producing B cells have been found at elevated levels in autoimmune 
disorders and mice lacking these B cells develop more severe arthritis and experimental 
autoimmune encephalomyelitis (EAE) [59, 123]. Regulatory T cells (Treg), which also 
produce IL-10, can play a role in regulating autoreactive B cell responses. It has been shown 
that the absence of functional human Tregs leads to the accumulation of peripheral 
autoreactive B cells [124]. Further, B cell-specific deletion of IL-10 in mice leads to Treg 
deficiency, which in turn leads to the accumulation of pro-inflammatory T cells and 
exacerbated arthritis [125].  
The importance of B cell-inhibitory receptors and signaling pathways was emphasized in 
section 1.2.3.4 and how the genetic deletion of FcγRIIB in mice leads to autoimmunity, 
largely due to the loss of the regulatory pathways described. In more detail, studies have 
shown that FcγRIIB is important for follicular exclusion of autoreactive B cells and also for 
regulating B cell activation by BCR-TLR co-ligation of ICs, a potent co-stimulatory 
mechanism of anergic autoreactive B cells alluded to earlier [126, 127]. The tyrosine kinase 
Lyn is involved in both activating and inhibitory signaling pathways in B cells. Because of 
the dual roles of Lyn its genetic deletion in mice have led to several observations of which 
one is the development of autoimmunity [128-130].  
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1.3.2 Systemic lupus erythematosus 
SLE is in its true sense a systemic autoimmune disease as it can give rise to symptoms in 
most organs in the body. SLE has a low prevalence with only approximately 1 case in 2500 
individuals in Northern Europe and 90 % of patients are women [131]. This supports a role 
for sex hormones in the pathogenesis of SLE but the mechanism behind this is still unclear 
[132, 133]. Patients can present with varying symptoms, all from rashes to anemia and 
psychosis. A characteristic of the disease is that symptoms arise suddenly, in so called flares, 
which are accompanied by periods of remission. Some of the most common known triggers 
of disease flares are UV-radiation and EBV infection [134]. How these disease flares relate to 
immune memory in the pathogenesis of SLE is the focus of paper II. Susceptibility gene loci 
have been identified for SLE and although they are important for the cause of disease, twin 
studies show that the concordance rate is fairly low. This indicates that environmental factors 
also play an important role for the etiology of SLE [135]. The presence of autoantibodies 
against self-antigens, such as double stranded DNA (dsDNA), in SLE patients is an important 
diagnostic marker. These autoantibodies form ICs with self-antigens and the ICs can settle in 
organs such as the kidneys and skin and the subsequent attraction of complement by the ICs 
causes local inflammation and tissue damage [136]. 
Apoptosis is a natural process that occurs in all tissues of the body. Although it occurs 
constantly, it is under normal conditions difficult to detect apoptotic cells in the blood or in 
tissues. However, they are found to a greater extent in SLE patients compared to healthy 
individuals [137, 138]. Autoantibodies with affinity for some of the antigens found on the 
blebbing membranes of apoptotic cells are present in SLE patients and there is considerable 
evidence supporting the fact that SLE patients have defects in the clearance of apoptotic cells. 
Some of the strongest evidence to support this is that the defect in some genes linked to 
apoptotic cell clearance can lead to SLE. Genes for which there is a strong link to disease 
development are encoding proteins that are in one way or another linked to apoptotic cell 
clearance. Examples are the complement component C1q, the phagocytosis enhancing Mer 
tyrosine kinase, the tingible body macrophage marker milk fat globule-EGF factor 8 (MFG-
E8) and the apoptotic cell binding phosphatidylserine receptor (PSR) [139-142]. Further, 
exposure of mice to apoptotic cells in increasing amounts gives rise to autoantibodies against 
the antigens presented on the apoptotic cells and sometimes disease manifestations. This has 
been shown both with intravenous injection of apoptotic cells derived from various cell 
sources, as well as skin UVB irradiation [143-147]. In the model employed to study B cell 
regulation in systemic autoimmunity in the papers of this thesis, thymocytes were induced to 
a state of apoptosis with in vitro dexamethasone treatment. The repeated intravenous injection 
of these into wild type (wt) mice gives rise to autoantibodies that are also present in SLE 
patients [148]. The fact that an increased load of apoptotic cells generates an autoimmune 
response is somewhat peculiar, as apoptotic cell death is normally associated with an anti-
inflammatory state [149]. This is true when apoptotic cells are successfully cleared from the 
body. However, a defect in clearance can lead to secondary necrosis of the apoptotic cells, a 
state where the cells still present apoptotic cell-derived self-antigens but that also promotes a 
pro-inflammatory response [150]. The combination of a pro-inflammatory milieu and the 
presence of modified self-epitopes on the apoptotic cells, which might not have been 
negatively selected against in central and peripheral checkpoints to the same extent as other 
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self-antigens, are likely to together be the cause of the transient autoimmune response in this 
model. 
SLE patients have an increased risk of developing cardiovascular disease (CVD) [151]. 
Although the mechanisms underlying this fact are not fully elucidated, it is clear that normal 
risk factors for CVD are not enough to explain this correlation. Alterations in immune 
function related to autoimmunity are however much more plausible and have to a certain 
extent been proven. Immune activation and the role of B cells in atherosclerosis will be 
considered in the next chapter and relates to our findings in paper I. 
 
1.4 ATHEROSCLEROSIS 
CVD is one of the leading causes of death worldwide [152]. Atherosclerosis is the most 
common underlying cause of acute cardiovascular events, such as myocardial infarction and 
stroke. Lipid-rich lesions in large and medium sized arteries form atherosclerotic plaques. 
The plaques build up slowly over decades and when a rupture of their cap structure occurs, it 
causes thrombosis and occlusion of the vessel, which leads to the often fatal cardiovascular 
events [153]. One of the major risk factors for CVD is high plasma cholesterol levels. 
Although lifestyle changes and pharmacological approaches to lower lipid levels has 
improved patient outcome and reduced mortality, CVD remains to be one of the major causes 
of death [154]. The involvement of the immune system in the pathogenesis of atherosclerosis 
is indisputable when looking at the cellular composition of atherosclerotic plaques, and 
atherosclerosis is considered as an inflammatory disease [155]. The increased risk of 
developing atherosclerosis in diseases like SLE, RA and psoriasis points to an important role 
for autoimmune regulation elements in the disease [151, 156, 157]. 
Infiltration of low-density lipoprotein (LDL) in the vessel wall is the initiator of plaque 
formation. When LDL accumulates in the subendothelial space of the vessel wall it can be 
modified by oxidative processes to form oxidized LDL (oxLDL). The lipid accumulation also 
causes the endothelial and smooth muscle cells to upregulate adhesion molecules and produce 
chemokines that will attract monocytes which can be retained by the adhesion molecules and 
further stimulated to differentiate into macrophages by M-CSF (macrophage colony-
stimulating factor) and GM-CSF (granulocyte-macrophage colony-stimulating factor), also 
produced by the endothelial cells [158]. Both monocytes and macrophages express PRRs that 
can bind variants of the lipids in the plaque. The scavenger receptors CD36 and SR-A 
(scavenger receptor class-A) on macrophages efficiently engulf lipids, causing the 
macrophages to eventually become lipid laden foam cells, the hallmark cellular component of 
atherosclerotic plaques [159]. Macrophages also express TLRs that can bind oxLDL, more 
specifically TLR2 and TLR4 have been shown to be activated by oxLDL. Interfering with the 
signaling pathway downstream of TLRs has been shown to reduce atherosclerosis, implying a 
pro-atherogenic role for these receptors [160-162]. Another innate sensor of oxLDL is the 
NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome which can be 
directly activated by cholesterol crystals [17]. The pro-inflammatory role of the 
inflammasome with production of IL-1β and IL-18 has been linked to the initiation and 
progression of atherosclerosis, as these cytokines cause enhanced vascular inflammation and 
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increase plaque instability [163, 164]. In apolipoprotein E deficient (Apoe-/-) mice, that 
develop hypercholesterolemia and atherosclerotic plaques spontaneously, IL-18 has been 
found at elevated levels and the lack of IL-18 in these mice was associated with a protective 
effect against disease development [165]. A similar protective effect was observed in Apoe-/- 
mice lacking IL-1β [166]. This finding was replicated in LDL receptor deficient (Ldlr-/-) 
mice, a mouse model of atherosclerosis where the mice are maintained on a high-fat diet. 
Reduced atherosclerosis development was observed when bone marrow derived cells lacked 
NLRP3 and IL-1β [17, 166]. 
T cells are also a significant cellular population in the atherosclerotic plaque and a role for 
adaptive T cell immunity in the pathogenesis of atherosclerosis is well established [167]. In 
Apoe-/- mice completely lacking B and T cells the development of atherosclerosis is 
significantly reduced and the transfer of CD4 T cells aggravates disease, suggesting an 
overall pro-atherogenic role for T cells [168]. Th1 responses have in numerous studies been 
shown to drive plaque development and this has been much attributed to their capability of 
producing IFNγ (interferon γ) which can activate monocytes, macrophages and DCs [169]. In 
experiments with Apoe-/- mice, the lack of IFNγ attenuates disease while the exogenous 
addition of it aggravates plaque formation [170, 171]. Tregs on the other hand have been 
shown to counteract the disease, promoting inflammation. This has been demonstrated by 
aggravated disease development when Tregs are depleted and the protective effect of Tregs 
has been associated with their capability to produce the anti-inflammatory cytokines TGF-β 
(transforming growth factor-β) and IL-10 [172-174].     
1.4.1 B cells in atherosclerosis 
The role of B cells in the pathogenesis of atherosclerosis has not been as extensively studied 
as the contribution of T cell mediated immunity and research so far has been contradictory. 
However relatively recent studies has shed some more light on how different B cell subsets in 
different ways contribute to disease outcome [175]. Unlike T cells, B cells are only present in 
the actual plaque at low numbers but are more abundant in so called tertiary lymphoid 
structures present in the adventitia surrounding arteries and could potentially from this site 
influence inflammatory processes underlying the disease [176]. The importance of B cell-
mediated humoral immunity in atherosclerosis has been appreciated for some time. The 
innate-like B1 cells and MZBs are sources of natural antibodies with an inherent reactivity 
for self-antigens, including oxidation-specific epitopes found on both oxLDL and apoptotic 
cells. An oxidation-specific epitope that has gained much attention in research related both to 
autoimmunity and atherosclerosis is PC. The natural antibody clone T15 binds to PC on both 
S. Pneumoniae, apoptotic cells and oxLDL, providing an interesting link between infection, 
autoimmunity and atherosclerosis. Several studies in mice have shown a correlation between 
anti-PC antibody responses and positive disease outcome [177-180]. In the studies alluded to, 
IgM antibody responses have mediated an atheroprotective effect. The role of IgG in 
atherosclerosis is however more unclear. IgG antibodies are present in atherosclerotic plaques 
and anti-oxLDL IgG antibody responses have been correlated with both positive and negative 
disease outcome [181, 182]. The role of IgG in atherosclerosis is further complicated by the 
fact that it binds to activating and inhibitory FcRs on cells both of the innate and adaptive 
immune system, making their direct effect more difficult to pinpoint [175]. 
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Some of the more convincing evidence supporting an atheroprotective role for B cells comes 
from a study where Apoe-/- mice were splenectomized and then received adoptive transfers of 
either B or T cells. Only B cell transfers protected from plaque development. Splenectomized 
mice developed more severe disease than did sham-operated mice, which is also in line with 
data showing that splenectomized humans have an increased risk of developing CVD [183, 
184]. Furthermore, Ldlr-/- mice fed a high-fat diet that received B cell-deficient bone marrow 
exhibited increased plaque formation compared to controls [185].  
The protective role of B cells is however complicated by the partial attenuation of 
atherosclerosis that anti-CD20 induced B cell depletion has resulted in, in both Apoe-/- and 
Ldlr-/- mice [186, 187]. Anti-CD20 treatment only effectively depletes B2 cells, which could 
suggest a protective role of B1 cells. BAFF is crucial for the maturation of B2 cells and 
BAFF-deficient Apoe-/- mice that almost completely lack B2 cells, but has an intact B1 
compartment, are protected from atherosclerosis [188, 189]. Contrary to this, it has been 
shown that adoptive transfer of splenic B2 cells from Apoe-/- mice to B cell deficient Apoe-/- 
mice, kept on a high-fat diet, was atheroprotective and that the protection was dependent on 
the transcription factor Id3 (inhibitor of differentiation-3) [190]. Out of the two B1 cell 
subsets most of the atheroprotective effects have been linked to the B1a cells and the role of 
B1b cells in atherosclerosis remains unclear. B1 cells are the main source of natural 
antibodies and it has been shown that the transfer of B1a cells from sIgM-/-mice, which 
express but do not secrete IgM, did not confer atheroprotection into splenectomized recipients 
like wt B1a cells did [191]. B1a cells are also the main producers of the anti-PC T15 antibody 
clone that has been linked to atheroprotection [177]. Splenectomy reduces the number of B1 
cells in the spleen, which could explain why splenectomy aggravates disease [192]. However, 
splenectomy also removes the marginal zone. MZBs are also producers of natural antibodies 
and their role in atherosclerosis, compared to FOBs which is the much more abundant B2 
cell, needs to be further elucidated. Another B cell subset whose role is yet to be established 
in atherosclerosis is the B regulatory cell. Although an atheroprotective role has been 
established for Tregs, recent studies on Bregs have come to conflicting results regarding the 
role for this elusive subset in atherosclerosis [193, 194]. 
 
1.5 CD36 
CD36 is a scavenger receptor expressed on a wide range of cells both in and outside of the 
immune system [195]. As most PRRs it is well conserved and has multiple orthologs in other 
species [196]. Being a scavenger receptor, CD36 recognizes a variety of ligands, such as lipid 
and lipoprotein components of bacterial cell walls, β-glucans on fungi, erythrocytes infected 
with falciparum malaria as well as self-antigens such as apoptotic cells and oxLDL [6, 197-
200]. For its ability to bind and internalize oxLDL, CD36 plays an important role in the 
pathogenesis of atherosclerosis [201]. Ligand binding to CD36 can result in several outcomes 
depending on the context, such as internalization and phagocytosis, pro-inflammatory 
responses and integrin activation. This is accomplished through various intracellular signaling 
events. Different signaling molecules and pathways have been implicated and they all involve 
Src family kinases and serine/threonine kinases of the MAPK family. In macrophages and 
platelets, Lyn and JNK are commonly involved in effector signaling, but in general the 
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signaling initiated by CD36 ligand binding seem to depend greatly on the cellular context 
[202-204]. In macrophages, CD36 can interact with both TLRs, TLR-heterodimers, 
tetraspanins and β integrins to mediate ligand uptake and intracellular signaling. CD36 was 
recently shown to internalize oxLDL through association with β1 and β2 integrins and 
tetraspanins CD9 and CD81, which in turn lead to phosphorylation of Syk and SHIP [205]. 
CD36 has also been shown to associate with the TLR heterodimers TLR1-TLR2, TLR2-
TLR6 and TLR4-TLR6 and downstream signaling events involve pathways including both 
JNK and Lyn [206-208]. 
CD36 was only recently appreciated for being expressed also on B cells and interestingly 
with a preferentially higher expression on MZBs compared to other B cell subsets. Higher 
expression of CD36 could also be seen on unswitched plasma cells in the TI response to S. 
pneumoniae, as compared to switched IgG1+ plasma cells. S. pneumoniae immunization of 
CD36 deficient (CD36-/-) mice resulted in lower levels of plasma cells and an impaired 
humoral response as compared to wt mice [51]. Another study has shown that CD36-/- mice 
infected with Leishmania major showed higher levels of specific IgG, smaller lesions and 
faster recovery after infection. In the same study, CD36 expression was found to be 
dependent on the transcription factor Oct-2 in B cells but not in DCs or macrophages [209]. 
In humans there is so far only one study that has reported CD36 expression on a fraction of 
CD19+ neoplastic B cells in patients with chronic lymphocytic leukemia [210]. In paper III a 
role for CD36 on B cells in the autoimmune response to apoptotic cells is investigated. 
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2 AIM 
 
The overall aim of my thesis was to study how B cell responses are regulated in systemic 
autoimmunity. 
The specific aims were: 
Paper I – To characterize the atheroprotective B cell response in the spleen and how it could 
be induced. 
Paper II – To investigate how memory to apoptotic cell-derived self-antigens develops and 
how it relates to SLE pathology. 
Paper III – To investigate the role of scavenger receptor CD36 on B cells in the autoreactive 
immune response to modified self-antigens.  
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3 RESULTS AND DISCUSSION 
3.1 A PROTECTIVE ROLE FOR B CELLS IN ATHEROSCLEROSIS  
The immune system plays a crucial role in the pathogenesis of atherosclerosis and B cells 
have been shown to have dual roles when it comes to good or bad outcome of the disease. In 
a study where Apoe-/- mice were splenectomized and then received a transfer of either B cells 
or T cells, it was shown that splenectomy aggravated disease and that only the B cell transfer 
conferred protection from developing atherosclerosis [183]. This proved that the spleen and 
in particular the splenic B cells were important for protective immunity. In paper I we wanted 
to further characterize the protective B cell response originating in the spleen, focusing on the 
different B cell subpopulations present there. In addition to this we know that the marginal 
zone of the spleen is an anatomical niche for trapping antigens carrying oxidation-specific 
epitopes and antibodies raised against these epitopes, as for example anti-PC antibodies, have 
been associated with protection from atherosclerosis [148, 179]. Therefore we also 
investigated the effects of immunizing wt and Apoe-/- mice with apoptotic cells carrying 
oxidation-specific epitopes and investigated how this affected the B cell response as well as 
the disease outcome.                                              
We investigated the frequency of different splenic B cell subsets in young non-atherosclerotic 
and aged atherosclerotic Apoe-/- mice as well as wt controls of both ages to get an indication 
as to which subsets could be of greater importance for the development of disease. We found 
that the precursor T1 and T2 B cell subsets both generally decreased with age in both strains. 
For the naïve B1 and B2 B cells in the spleen the most pronounced difference when 
comparing young and old Apoe-/- mice was observed in the MZB population, which was 
significantly increased in old Apoe-/- mice. Lastly, when investigating activated B cell subsets 
in the spleen of the same mice, we found significantly increased levels of both GC B cells 
and antibody-forming cells (AFC). This showed that there is an ongoing spontaneous 
activation in the spleen of aged Apoe-/- mice (Figure 3). When mice and humans age there is a 
reduced output of B cells from the bone marrow, which is compensated for by expansion in 
the periphery [211]. In the aged Apoe-/- mice we found reduced levels of bone marrow-
derived T1 precursors together with an expansion of MZBs as well as an adaptive B cell 
activation. This prompted us to investigate the clonality of the expanded B cell subsets in 
aged Apoe-/- mice compared to wt controls. Using the method of spectratyping we could 
expand the VDJ region of different heavy chain variable region (Vh) families. In the Vh5 and 
Vh7 families the pattern of clonal expansion differed between Apoe-/- and wt mice showing 
that certain clones were preferentially expanded in the Apoe-/- mice. Interestingly, these Vh 
families are both known to harbor recombination combinations giving rise to anti-PC 
reactivity. In line with this, we could also detect increased levels of antibodies towards PC as 
well as oxLDL in the atherosclerotic Apoe-/- mice, confirming that there is actually an 
expansion of antibodies with the types of reactivities belonging to the Vh5 and Vh7 families. 
This suggested that expansion was driven by disease and not age. 
Atherosclerosis is characterized by an increased amount of circulating lipids as well as 
oxidized lipids. These are constantly being filtered through the marginal zone of the spleen, 
where they can be bound by both MZM and MZB. This made us curious as to whether lipids 
could actually accumulate also in the spleen, as they do in vessel walls, to locally drive the 
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immune response. Indeed, we found lipid accumulation in red pulp macrophages in the 
spleens of aged Apoe-/- mice. We then hypothesized that these lipids could drive 
inflammasome activation in the spleen, since cholesterol crystals have been shown to directly 
activate this multiprotein complex and that this activation subsequently has implications for 
atherogenesis [17]. Inflammasome activation can be measured by caspase 1 activity and we 
found increased levels of caspase 1 in splenic macrophages and neutrophils in aged Apoe-/- 
mice. Furthermore, we could also induce inflammasome activation in the same types of cells 
by injecting wt mice intravenously with either oxLDL or apoptotic cells, which present the 
same epitopes found on for instance cholesterol crystals. We could for the first time show that 
during atherosclerosis, lipids accumulate not only in the plaque but also in the spleen and 
cause inflammasome activation and caspase 1 activity in macrophages and neutrophils. The 
subsequent release of IL-1β from these cells could potentially work as an adjuvant for the B 
cell response originating in the spleen [212]. 
 
Figure 3. Frequency of GC B cells and antibody-forming cells (AFCs) determined by flow cytometry. Both subsets are 
increased in the spleens of old Apoe-/- mice compared to wt controls. n=7-10.  
It has already been shown that immunizing mice with various foreign antigens containing 
PC-epitopes can be atheroprotective [179]. Here, we immunized young Apoe-/- mice repeated 
times with self-antigens in the form of apoptotic cells, which carry oxidation-specific 
epitopes such as PC, to test whether this could induce a B cell response similar to the 
spontaneous ongoing B cell response already seen in the old atherosclerotic Apoe-/- mice. The 
apoptotic cells would be injected intravenously, get trapped in the marginal zone of the spleen 
and induce inflammasome activation, which we hypothesized would augment the B cell 
response originating there and we now wanted to investigate whether this could also be 
beneficial for the outcome of atherosclerosis development. Strikingly, Apoe-/- mice that had 
received apoptotic cell injections during the course of disease development, showed 
significantly smaller plaques in both the aortic root and arch compared to non-injected 
controls. This was also accompanied by a drop in serum cholesterol levels (Figure 4). In order 
to further show that the protective effect was specifically contributed by the B cell response, 
we performed the same experiments in Apoe-/- mice crossed to the B cell-deficient µMT 
mouse strain. There was no difference in the severity of atherosclerosis with regards to either 
plaque formation or serum cholesterol levels in apoptotic cell-injected µMTApoe-/- mice 
compared to non-injected controls. The protective effect of the apoptotic cell injections was 
consequently B cell-dependent. 
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We also investigated the B cell response following apoptotic cell injections in Apoe-/- mice 
compared to wt controls. There was no increase in MZBs in Apoe-/- or wt mice following 
apoptotic cell injections, however there was a significant increase in GC B cells and AFCs in 
both groups of mice following injections. Injections of apoptotic cells were also given to 
NOD-like receptor family pyrin domain containing 3-deficient (Nlrp3-/-) mice, which lack 
functional inflammasomes, and they failed to mount an anti-PC antibody response, 
suggesting that additional induction of the protective B cell response from the inflammasome 
is needed. 
Paper I describes the splenic B cell response in atherosclerosis and pinpoints specific immune 
cells and regulatory pathways that are important for the development of protective immunity 
against the disease. It also shows how the protective response can be induced and highlights 
important similarities that the induced response has with the one in spontaneous disease. 
Finally, it establishes the importance of how immune activation in atherosclerosis partly 
originates in the spleen and this link will be valuable for future research. 
 
Figure 4. Representative pictures of lesions in the aortic root stained with oil red o. Apoptotic cell-injected Apoe-/- mice show 
reduced lesion size as compared to uninjected controls. n=6-7. On the right, cholesterol levels measured at day 26 using an 
enzymatic colorimetric assay. Apoe-/- mice show lowered cholesterol levels after apoptotic cell injections while there is no 
difference in µMTApoe-/- mice. The µMTApoe-/-mice also exhibited higher cholesterol levels after apoptotic cell injections 
than did Apoe-/- mice. n=6-9. 
 
3.2 IMMUNOLOGICAL MEMORY TO APOPTOTIC CELL-DERIVED SELF-
ANTIGENS 
Immunological memory is one of the most fundamental features of the immune system and a 
crucial mechanism to rapidly and efficiently clear recurring infections. The basic concept is 
that antigen specific long-lived memory B and T cells are formed after a primary infection 
and being already antigen experienced, they are then able to more rapidly respond to and 
clear a secondary infection with the same pathogen [31]. However, if the antigen in question 
is a self-antigen, as is the case in autoimmune disease, the memory response becomes more 
complex, since a self-antigen will not appear instantly like a pathogen but is more or less 
always present. Patients with the autoimmune disease SLE suffer from so called flares, which 
are sudden exacerbations of disease activity followed by periods of remission. These flares 
are often brought on by environmental triggers such as UV light, drugs and viral infections 
[213]. This kind of quick immune activation, shortly after being exposed to triggers that 
could enhance the presence of self-antigens, is similar to what would happen as a 
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consequence of immunological memory activation. In paper II we wanted to investigate the 
involvement of autoreactive immune memory in SLE pathogenesis in the context of B cell 
responses to apoptotic cells. We wanted to explore in more detail features of the memory 
response such as longevity, affinity maturation and specificity; aspects of autoreactive 
immune memory that remain relatively unexplored. 
To study autoreactive immune memory we used the same model as in paper I and injected wt 
mice intravenously with syngeneic apoptotic cells to break tolerance to the self-antigens 
present on these cells. As expected, the mice developed increasing titers of both anti-DNA 
and anti-PC IgG over time. This response is however transient and about a month after the 
last apoptotic cell injection the autoantibody titers almost returned to baseline. Another month 
after this, we gave the mice a single boost injection of apoptotic cells in an attempt to recall 
the primary response. Indeed, the boost injection of apoptotic cells led to an increase in both 
anti-DNA and anti-PC antibodies and the response was both specific and quick, much like in 
classical immune memory (Figure 5). Autoantibodies can form ICs that in turn can 
accumulate in small blood vessels causing tissue injury and organ dysfunction [214]. We 
went on to test whether the autoantibodies in the memory response, as compared to 
antibodies from pre-immune (pi) serum or from the primary response, could be more 
pathogenic and thereby lead to kidney damage in the mice. In kidneys of mice having 
received the first boost injection there was little sign of Ig deposition. However, we also 
performed experiments where mice were subjected to a second boost injection of apoptotic 
cells about one month after the first boost. In the kidneys of these mice there was clear Ig 
deposition and the glomerular architecture was also altered, indicating kidney damage, 
possibly due to IC accumulation and increased complement activation [214]. Serum from 
mice having received the second boost also showed positive anti-nuclear antibody (ANA) 
staining with different staining patterns. No ANA-reactivity was detected in serum from mice 
that had only received the first boost. These experiments show a clear memory response 
against modified self-antigens found on apoptotic cells. The response is rapid as well as 
specific, since control experiments using a TD antigen, either in combination with apoptotic 
cells or without, showed no difference in the subsequent TD response. The memory response 
to the self-antigens also had pathological features but interestingly only in the second recall 
response, indicating that the memory response contains steps of immune activation that lead 
to increased pathology. 
 
Figure 5. Serum levels of anti-DNA and anti-PCIgG measured by ELISA. Wt mice were administered apoptotic cells at the 
time points indicated by arrows. Increasing autoantibody titers was observed in the primary response and a rapid increase 
after the first boost injection.   
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In a memory response, the antigen specific 
memory B cells undergo further subclass 
switching and SHM leading to more 
switched memory B cells and antibody 
responses with higher affinity for the 
antigen. Other cells of the adaptive and 
innate immune system such as TFH cells and 
DCs are also involved in these processes 
[215]. Using the same model, we further 
characterized the different players that could 
contribute to the memory response to 
modified self-antigens. In the spleen of mice 
having received the first or the second boost 
of apoptotic cells, compared to pi or the 
primary response, we found elevated levels 
of IgG2a- and IgG2b-switched plasma cells, 
GC B cells and TFH cells. In addition, we 
could in histology spleen sections see a 
striking    expansion of IgG+ plasma cells in 
extrafollicular foci. A majority of these 
could also be identified as PC-reactive since 
they stained positive for the T15-clone, 
which is the prototypic anti-PC clone [216]. 
This data shows that the memory response 
against apoptotic cell-derived self-antigens 
contains many of the hallmarks of adaptive 
immunity. 
We performed a classic transfer experiment to further verify that the memory response we 
saw was real and specific to the self-antigens of interest. Splenocytes from mice that had 
received the primary immunization of apoptotic cells or splenocytes from pi mice were 
transferred to irradiated recipients that were then boosted with a single injection of apoptotic 
cells or given no injection. The boost injection elicited an autoreactive memory response only 
in the mice that had received self-antigen experienced splenocytes and again we could show 
that this memory response contained all the elements of a classical adaptive immune response 
as previously characterized. 
Apoptotic cells are complex antigens and present a range of epitopes on their blebbing and 
budding plasma membrane [217]. Apart from the antigens we had already looked at, we 
therefore wanted to investigate other possible reactivities relevant to apoptotic cells and 
autoimmunity and what the reactivity pattern and intensity would look like in a primary 
response to apoptotic cells as compared to the memory response. To help us with this 
question we used an array with 61 different autoantigens [218, 219]. Sera from both pi as 
well as mice that had received either the primary or first boost immunization were tested for 
the autoantigen reactivities. Interestingly, as much as 19 of the autoantigen reactivities turned 
out to in varying degrees be enriched in the sera from the memory response (Figure 6). The 
Figure 6. Serological spectrum of IgG autoreactivity in pi, 
primary and the first boost response investigated using an 
autoantigen microarray. The heat map shows the reactivity 
to 61 autoantigens meeting the minimal normalized 
fluorescence intensity requirement. The signal intensities 
are depicted on a relative scale. Blue, black and yellow 
represent Ag reactivity intensities below, close to and 
above the mean, respectively. Ag reactivity clusters are 
indicated at the left edge of the heat map. This array shows 
that the memory response against apoptotic cell-derived 
self-antigens is selective. 
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strongest response was detected for the Sm/RNP antigen, which is actually one of the anti-
nuclear antigens with most clinical significance, as IgG-titers with this specificity are used as 
a diagnostic criterion for SLE [220]. 
Antibody responses are regulated through both positive and negative feedback mechanisms 
that are dependent on FcRs [29]. In a memory response, where antigen-specific antibodies are 
already present upon re-encounter of the antigen, the FcR-dependent feedback mechanisms 
are also of importance for the efficiency of the response. We wanted to study these 
mechanisms in the memory response to self-antigens. Apoptotic cells were coated with serum 
from either pi mice or mice that had received the primary or first boost immunization. IgG 
antibodies from first boost serum showed most efficient opsonization of the apoptotic cells 
and in line with this, first boost serum-coated apoptotic cells were preferred targets of 
phagocytosis by macrophages in vitro. In in vivo experiments, where mice were injected with 
serum-coated apoptotic cells from the same groups as mentioned and the subsequent antibody 
and B cell responses were measured, we found that mice immunized with boost-coated 
apoptotic cells had a stronger response. In both the phagocytosis and the in vivo assay we also 
included a group where the coated apoptotic cells were pretreated with protein G to assess 
dependency on FcR-mediated regulation. We could indeed show that the increased response 
elicited by autoantibodies from serum from the memory response is at least in part FcR-
dependent. 
Paper II shows that there is a memory response towards the self-antigens present on apoptotic 
cells. It also shows that this memory response is more pathogenic than the initial break of 
tolerance and how the pathogenicity relates to the pathophysiology of SLE. It also sheds light 
on the fact that a lot but not all of the features in a classical memory response, which we have 
learned about from immune responses against foreign antigens, also hold true for this 
autoreactive memory. The findings in this study will be valuable for further studies on 
understanding how immune memory relates to SLE pathology and how to steer the response 
to self-antigens away from the part of the memory response leading to pathogenicity and 
worsened disease.  
3.3 CD36 PLAYS A ROLE IN AUTOREACTIVE B CELL RESPONSES 
CD36 is a scavenger receptor that is expressed on various immune cells but has mostly been 
studied on macrophages in the context of atherosclerosis for its ability to bind to epitopes on 
oxLDL [221]. CD36 is however also expressed on B cells and a few years ago it was found to 
be preferentially higher expressed on MZBs compared to other peripheral B cell subsets [51]. 
Being a scavenger receptor, CD36 binds to various ligands and amongst them antigens that 
express oxidation-specific epitopes, such as apoptotic cells. In paper III we investigated the 
role of CD36 on B cells in the context of autoimmune responses to modified self-antigens 
found on apoptotic cells and how this could affect subsequent B cell activation once tolerance 
to these antigens was broken. 
To study these questions we used the same apoptotic cell model as described in paper I and 
II, which we applied or studied in a CD36-deficient (CD36-/-) mouse. When characterizing 
the peripheral B cell compartment in the CD36-/- mouse we could not find any differences in 
the frequencies of T1 and T2 B cells or in the mature FOB and MZB subsets as compared to 
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wt controls. We also investigated how CD36-/- B cells responded to either the TI-II antigen 
NP-Ficoll or the TD antigen NP-CGG, using mixed bone marrow chimeras. The bone 
marrow chimeras were lethally irradiated wt mice that had received a mix of congenic wt and 
CD36-/- bone marrow or as controls wt mice with a mix of congenic wt and wt bone marrow. 
There were no major differences in the way B cells lacking CD36 responded to either the TI 
or TD antigen with regard to GC and plasma cell responses in the spleen. NP-specific 
antibody responses in sera of the CD36-/- bone marrow chimeras compared to controls were 
also measured and no difference in the response could be detected. CD36 therefore does not 
affect peripheral B cell development or the ability of B cells to respond to TI or TD antigens. 
However, we hypothesized that CD36 could be involved in the regulation of an immune 
response against self-antigens, such as those found on apoptotic cells. Mixed bone marrow 
chimeras, immunized with apoptotic cells, showed a significant expansion of CD36-/- B cells 
into GC B cells and unswitched plasma cells compared to wt B cells (Figure 7). CD36-/- 
chimeras compared to wt controls also exhibited increased levels of anti-DNA IgG 
antibodies. The significantly increased expansion of GC B cells and unswitched plasma cells 
in the CD36-/- B cell compartment indicated that CD36 plays an inhibitory role in the 
response to modified self-antigens and that this had consequences for the development of 
autoantibodies. 
 
Figure 7. Frequency of GC B cells, unswitched and switched plasma cells (PC) in the spleen of mixed bone marrow chimeras 
with a mix of  congenic wt and CD36 deficient (-/-) bone marrow. Mice were left untreated (no apo) or received apoptotic cell 
injections (4x apo). CD36 deficient B cells were more prone to enter the GC and differentiate to unswitched plasma cells, but 
here was no significant difference for switched plasma cells. n=5.    
Next, we investigated how CD36 might convey the inhibitory effect observed in the response 
to apoptotic cells. Since CD36 does not have any signaling motifs of its own, it requires the 
engagement of a signaling partner. CD36 has been shown to associate with the tyrosine 
kinase Lyn in macrophages [208]. Performing a co-immunoprecipitation of Lyn and CD36 in 
a B cell line, we found that CD36 associated with Lyn also in B cells. Lyn has the ability to 
initiate activating signaling downstream of the BCR but it is also involved in inhibitory 
signaling, as it can phosphorylate the phosphatase SHIP downstream of FcγRIIb that in turn 
inhibits signaling through the BCR [96]. We therefore also investigated how CD36 interacted 
with the BCR and FcγRIIb using an advanced imaging technique where co-localization of 
receptors can be visualized and quantified on a single cell membrane [222]. At steady state, 
CD36 co-localized with the BCR, but upon crosslinking of FcγRIIb CD36 instead co-
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localized with this receptor (Figure 8). Based on this data, associating CD36 with both Lyn 
and FcγRIIb, we next investigated SHIP phosphorylation in wt and CD36-/- B cells. Levels of 
phosphorylated SHIP were similar in anti-IgM stimulated wt and CD36-/- B cells, which led 
us to believe that other signaling proteins or pathways downstream of the BCR or FcγRIIb 
were involved. A possible candidate was the pathway regulated by Btk and JNK to induce 
apoptotic signaling as a consequence of IC crosslinking of FcγRIIb [99]. More evidence to 
support a role for CD36 in the IC-induced signaling pathway was found by performing an in 
vitro plasma cell killing assay, where B cells from wt or CD36-/- mice were first stimulated 
with LPS to induce plasma cell generation and then crosslinked with either an anti-FcγRIIb 
antibody or an isotype control. After antibody crosslinking the levels of apoptotic plasma 
cells were measured using flow cytometry. As expected there was an increased level of 
apoptotic plasma cells from wt mice but not for CD36-/- mice, indicating that regulation of 
plasma cell apoptosis is at least in part CD36-dependent. 
 
Figure 8. Pearson's co-localization coefficient for CD36 and IgM or FcγRIIB in images of CH27 cells at 5 and 10 min after 
being added to lipid bilayers containing either ICAM-1 alone, or ICAM-1 in combination with anti-rat Fc or anti-rat Fc + rat 
anti-CD32 antibody. The images were analyzed for co-localization and each symbol represents an individual cell. At steady 
state CD36 co-localized with the BCR but upon engagement of FcγRIIB, CD36 leaves the BCR and instead co-localizes with 
this receptor. n=6-39. 
Another interesting observation in wt mice in the response to repeated apoptotic cell 
injections was that as the B cell response was induced over time, when self-tolerance was 
broken, the frequency of CD36-expressing MZBs was lowered. About two weeks after the 
last injection of apoptotic cells, the frequency of CD36+ MZBs was restored to normal levels. 
The lowered CD36 expression could be due to down-regulation of CD36 on a transcriptional 
level, changes in the processes of internalization and recycling of the receptor or a preference 
for activation and proliferation of CD36-expressing MZBs into activated B cell subsets. 
Further studies are needed to answer these questions.  
From the work using mouse models not a lot is known about the role of CD36 on B cells and 
even less is known about the expression pattern and role of CD36 on B cells in humans. We 
therefore sought to explore this, firstly by investigating the expression of CD36 on different 
peripheral B cell subsets using peripheral blood mononuclear cells (PBMC) from healthy 
donors. We found that CD36 was indeed expressed on naïve B cells, memory B cells as well 
as circulating MZBs. As opposed to CD36 expression in mouse it does not seem that MZBs, 
at least in the periphery, have a higher expression of CD36 compared to other B cell subsets. 
Having validated the expression of CD36, we moved on to compare levels of CD36-
expressing B cell subsets in PBMCs from healthy donors compared to SLE patients. The 
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levels of CD36-expressing MZBs were significantly lower in the SLE patients compared to 
healthy individuals, although there was no major difference in levels of memory B cells or 
total B cells expressing CD36. This was a very interesting and potentially important finding 
as it correlated with the lowered CD36 expression we had observed in mice following 
apoptotic cell injections.  
Paper III shows an inhibitory role for CD36 on B cells in the autoreactive immune response 
to modified self-antigens with consequences for the subsequent expansion of activated B cell 
subsets and autoantibody responses. CD36 most likely accomplishes this regulation through 
associating with known regulators of inhibitory B cell signaling, namely FcγRIIb and Lyn. It 
also shows a role for CD36 in regulating plasma cell apoptosis through an FcγRIIb-mediated 
pathway. This is an important means of regulation for the model we are studying, where ICs 
of autoantibodies and apoptotic cells are likely present and apoptosis induced by ICs is a 
mechanism to attenuate the immune response. It also shows how chronic systemic exposure 
to apoptotic cells decreases levels of MZBs expressing CD36. In SLE, where defects in 
removal of apoptotic cells are linked to risk for developing the disease, levels of peripheral 
MZB expressing CD36 are also lowered. Thus, finding ways to maintain CD36 expression on 
B cells could lead to new therapeutic targets.    
3.4 FINAL REFLECTIONS AND FUTURE PERSPECTIVES 
This thesis provides insight into how B cell responses are regulated in an autoimmune context 
and how this relates to the pathogenesis in atherosclerosis and SLE. More specifically the 
major findings are: 
• The description of a protective B cell response in atherosclerosis originating in the 
spleen and induced by the oxidation-specific epitopes arising during sterile 
inflammation. 
• An immunological memory response to apoptotic cell-derived self-antigens with 
some of the traits of a classic memory response and with implications for the 
pathogenesis of SLE. 
• A role for the scavenger receptor CD36 on B cells in regulating an autoreactive 
immune response in a negative manner by associating with known B cell inhibitory 
components Lyn and FcγRIIB. 
Paper II characterizes the memory response to apoptotic cell-derived self-antigens and shows 
how it relates to SLE pathology. Except for one published study where an increase in anti-
cardiolipin antibodies upon re-immunization with apoptotic cells was observed, our study is 
first of its kind to show a memory response to apoptotic cell-derived self-antigens and how 
this memory response exhibits a lot of the same features as classic immunological memory, 
but interestingly also lack some, such as affinity maturation [143]. Disease flares in SLE 
patients are usually caused by environmental triggers, which can also lead to a rapid increase 
in the load of apoptotic cells. Hence, the finding that boosts of apoptotic cells following 
primary immunization led to memory activation accompanied by increased pathology for 
every subsequent recall response was an interesting link to flares in SLE patients. It is also an 
important finding as we could characterize this memory response and highlight what cellular 
components and specific antibody responses get reactivated and therefore could be involved 
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in the initiation of these flares. To further support the relevance of our findings for SLE 
pathology we found, using the autoantigen array, that the autoantibody profile in the memory 
response was selective to several different apoptotic cell-derived self-antigens. The strongest 
antibody response in the memory response was against the nuclear antigen Sm/RNP, which 
has not only been linked to SLE pathology in humans but is actually one of the serological 
diagnostic criterions. There was an increase in GC B cells and TFH cells in the memory 
response but at least for the anti-PC response there was no affinity maturation in the recall 
antibody response. However, since antibody responses towards several apoptotic cell-derived 
antigens were present in the memory response, it remains to be investigated whether 
antibodies with those reactivities have gone through affinity maturation. There was also a 
clear expansion of extrafollicular foci with both unswitched and isotype switched plasma 
cells. This leaves one wondering if the follicular or extrafollicular activation pathway is of 
more importance for an autoreactive memory response and to what degree the memory B 
cells require T cell help to get reactivated. To answer some of these questions an AID-
reporter mouse could be used where all B cells that have expressed AID, and therefore would 
have received T cell help, will be GFP-tagged. It would demonstrate how abundant the 
contribution of T cell help is to the formation of the extrafollicular foci in the memory 
activation. It should however be mentioned that this system is complicated by the fact that 
also developing B cells can express AID to some extent in a TI manner with the use of BCR 
and TLR signaling alone [223]. Another approach could be to in more detail characterize the 
memory B cells in this model of autoimmune memory with specific memory markers such as 
CD80, CD73 and CD35. Apart from actually showing the presence of bonafide memory B 
cells in the model, these markers can also be correlated to V region mutation status [224]. 
Paper I dissects the protective B cell response in the spleen of atherosclerotic Apoe-/- mice, as 
transfer of B cells from atherosclerotic mice to young non-atherosclerotic Apoe-/- mice had 
previously been shown to protect against disease development [183]. The role of B cells in 
atherosclerosis is only beginning to be unraveled and when it comes to an atheroprotective 
role for B2 cells, published work shows contradictory results. Although some studies of anti-
CD20 B2 cell depletion shows a positive correlation with disease outcome, a problem with 
these studies is that they do not discriminate between the contributions of FOBs versus 
MZBs. It is likely that the protective effect seen is mostly attributed to depletion of the FOBs, 
as these are more prone to engage in TD responses and can therefore possibly produce more 
pathogenic antibodies that could increase plaque development and instability. MZBs on the 
other hand, more readily engage in TI responses and are known producers of anti-PC IgM, 
both as natural antibodies and in response to S. Pneumoniae [225]. In paper I we found a 
striking expansion of the MZB pool but no increased expansion of FOBs in the old Apoe-/- 
mice, suggesting that the MZBs are a more likely candidate subset for conveying the 
protective effect. We cannot rule out the contribution of protective effects contributed by B1 
cells in our study but B1 cells were not expanded in the aged mice either in the spleen or the 
peritoneum. The role of MZBs in atherosclerosis needs to be further elucidated and one 
approach could be to cross the Apoe-/- strain to a mouse strain with specific deletion of MZBs 
to assess the actual contribution to atheroprotection. To avoid defects associated with a lack 
of MZBs another approach could be to use an Apoe-/- mouse with MZBs with a mutated BCR 
lacking affinity for oxLDL. In paper I we were also able to induce the atheroprotective B cell 
response by immunizing young non-atherosclerotic Apoe-/- mice with apoptotic cells with 
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some of the same oxidation-specific epitopes as those present on modified lipids. It was very 
interesting to discover that this immunization was driving a B cell response very similar to 
the spontaneous ongoing B cell response in old atherosclerotic mice. This means that if the 
protective response can be induced at an early stage it can protect from disease development. 
The use of vaccination strategies for atherosclerosis is undeniably something that is emerging 
as a therapeutic approach and the body of work where different vaccination models have been 
tested in pre-clinical trials now sets the stage for large long-term clinical studies [226]. As a 
continuation of this project we aim to use the concept of autoimmune memory shown in 
paper II to induce a primary transient immune response against apoptotic cells in a mouse 
strain where the deletion of ApoE can be induced with tamoxifen treatment. This means we 
can control the onset of disease and we hypothesize that memory to apoptotic cell-derived 
self-antigens can be recalled by the induction of oxidation-specific epitopes arising during the 
course of atherosclerosis development and that the more rapid memory response could 
protect from plaque formation and disease. Something to keep in mind though is that the 
autoimmune memory response in paper II was accompanied by increased kidney pathology. 
However, the memory response could behave differently when it is evoked by 
atherosclerosis-associated antigens sharing molecular mimicry with apoptotic cells and could 
therefore result in a more protective phenotype. This remains to be evaluated.     
Paper III demonstrates a role for the scavenger receptor CD36 on B cells in negatively 
regulating the autoimmune response to apoptotic cells. We have found that CD36 can 
associate with both Lyn and FcγRIIB, which are known negative regulators of B cell 
activation. It is therefore likely that CD36 upon binding apoptotic cell-derived self-antigens 
associates with these receptors to exert its inhibitory effects by affecting subsequent 
downstream signaling. That CD36 upon ligand binding can influence intracellular signaling 
has been shown for macrophages in numerous studies. The association with Lyn makes it 
possible for CD36 to activate SHIP downstream of FcγRIIB. However, in vitro stimulation 
assays of wt B cells compared to CD36-deficient B cells show no major difference in SHIP 
phosphorylation. We will therefore look further into a SHIP-independent pathway 
downstream of FcγRIIB involving Btk and JNK. This pathway is important for selection in 
the GC and in plasma cell apoptosis and is induced by ICs, which would likely be present in 
increased amounts following repeated injections of apoptotic cells. The in vitro data showing 
that plasma cell apoptosis following cross-linking of FcγRIIB is CD36-dependent further 
supports a role for CD36 in regulating this pathway. In addition CD36 has been shown to 
induce JNK-signaling in human cell lines [207]. Further studies involving in vivo and in vitro 
experiments with ICs with self-antigens are needed to discern the signaling pathways in B 
cells affected by CD36 in this model. After repeated apoptotic cell injections and break of 
tolerance to self we found that levels of CD36-expressing MZBs was dramatically decreased. 
Whether this is due to increased internalization, downregulation or an increased activation 
and differentiation of CD36+ MZBs into GC B cells and plasma cells remains to be 
investigated. This however will be an important direction of the project since our 
investigations of CD36 expression on human peripheral B cells in SLE patients led us to find 
that similarly to the findings in wt mice, SLE patients have lower levels of CD36+ peripheral 
circulating MZBs. To investigate how FcγRIIB expression correlates to CD36 expression on 
human B cells as well as to investigate in vitro signaling on CD36 expressing B cells in SLE 
patients compared to healthy individuals will be of great value. A few years back it was 
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established that CD36 expression in B cells is dependent on a different transcription factor 
than in macrophages or DCs, suggesting that a different transcriptional network could also be 
involved in the signaling and function of CD36 on B cells. Unraveling this network could 
provide more clues to the role of CD36 on B cells in different contexts.  
I would like to conclude that the work in this thesis has led to the discovery of an inducible 
atheroprotective B cell response, characterization of the autoimmune memory response to 
apoptotic cell-derived self-antigens and the discovery of CD36 as a regulator of autoreactive 
B cell responses. The results provide a deeper understanding for the complexity of B cell 
regulation in autoimmunity and have implications for the treatment of atherosclerosis and 
SLE.            
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